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Abstract
There are many ways to fight cancer using the body’s own immune system. Some methods include the administration of
vaccines while others involve stimulatory factors injected near tumors. One promising method is enlisting the help of T cells.
To fight cancer effectively, T cells must be able to recognize cancerous antigens and the environment in which these T cells
reside must be conducive to their function, survival, and proliferation.This paper discusses a method of providing such an environment called adoptive cell transfer, as well as the elements that effect this protocol and the ways in which the environment
can be manipulated to increase the effectiveness of adoptive cell transfer.
Many factors contribute to the observation that the effectiveness of adoptive cell transfer increases as immunodepletion increases, namely, the depletion of regulatory T cells.Additionally, the existence of natural killer cells during adoptive cell transfer
has been shown to decrease its effectiveness. Also, increased levels of cytokines IL-7 and IL-15 enhance the function, survival
and proliferation of transferred T cells which would increase their effectiveness. Moreover, the results of adoptive cell transfer
are more positive when patients’ own T cells are used.
These findings show that T cells can be used through adoptive cell transfer as an effective treatment for metastatic melanoma
patients, and that there is potential for adoptive cell transfer to be adopted as a widespread effective treatment for cancer.
Introduction
Cancer is a disease characterized by the presence of mutated
cells that continue to divide uncontrollably. Cancerous, or malignant, tumors, can spread to other parts of the body especially
via the lymph system which can act like a cancer highway, and
new tumors can then form in places far from the original tumor
source (What is Cancer 2015).These tumors can have negative
health effects and in many cases can be life threatening.
According to the World Health Organization more than 14 million new cancer cases were diagnosed in 2012 and there were
more than 8 million deaths attributed to cancer. Additionally,
the American Cancer Society projects the number of new cancer cases in the United States in 2015 to exceed 1.5 million and
the number of deaths to exceed a half million.
Radiotherapy, a common cancer treatment, works by directing
high energy beams, including x-rays and gamma rays, at cancer
cells to disrupt their DNA and ultimately result in cell death
(“Radiation Therapy”). Although radiation therapy can be successful at eradicating cancerous cells, relapse is a common
problem because a few cells, or even just one cell, left behind
can continue to divide and pose a serious health risk (Wayteck
et. al., 2014).
To combat the problem of relapse, chemotherapy is commonly prescribed to ensure that all cancerous cells are eradicated. Chemotherapy works by killing all rapidly dividing cells
(“Chemotherapy”). However, chemotherapy has many unwanted
side effects as it does not differentiate between healthy rapidly dividing cells and cancerous rapidly dividing cells. This effects many
different systems within the body and can cause anemia, hair loss,
infection and other unhealthy and unwanted symptoms.
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Another form of treatment, immunotherapy, works by using
immune elements to target cancerous cells through recognition of cancer antigens. There are two different ways of recognizing cancerous cells through antigens. One way is through
tumor specific antigens which are expressed solely in cancerous tumor cells, while the other involves overexpressed antigens which more abundant in cancerous tumor cells than in
healthy cells. This method of treatment aims to avoid the side
effects of chemotherapy by targeting only cancerous cells and
to also thwart the problem of relapse seen in radiation therapy
(Wayteck et. al., 2014).
Passive immunotherapy uses stimulatory factors such IL-2
which is injected into the tumor area to stimulate anti-tumor
T cells to proliferate, activate, and increase effector functions
(Wayteck et. al., 2014). Active immunotherapy, on the other
hand, involves CD 8 and CD4 T cells that are primed to recognize specific cancerous antigens and thereby direct immune
cells to target and kill these cancerous cells. This report discusses the effectiveness of active immunnotherapy in general
and, specifically, a branch of active immunotherapy called adoptive cell transfer.

Methods
To research the effectiveness of active immunotherapy and specifically adoptive cell transfer, relevant information was gathered
from many databases and journals. Those databases included:
the Touro College Library database, Proquest Science Journals,
Pub MEDLINE (EBSCO), and Oxford Journals. The information
gathered was narrowed further and analyzed to glean an understanding of the effectiveness of these treatment protocols.
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Discussion
A recent study indicates that active immunotherapy can be an
effective treatment for cancerous tumors (Raez, et. al. 2003). This
study assessed the impact and response of CD8 T cells to tumorcell-based allogeneic vaccines in patients with advanced non-smallcell carcinoma, commonly known as lung cancer. However, the
selection of patients with advanced stages of non-small-cell carcinoma may have resulted in reduced effectiveness of treatment,
as cancerous cells may have been too numerous for the body’s
immune system to handle. Similarly, as only patients previously
unresponsive to conventional treatments like chemotherapy and
radiation therapy were studied, the results may have been lower
than they might be had the body’s ability to fight off harmful cells
not already been undermined.

Vaccinations were delivered in three courses. After completion of the first course, only patients with stable disease
progression or positive response against non-small-cell carcinoma as determined by CT scan, coupled with low toxicity,
continued to a second course of vaccination. Again, patients
with no tumor progression and non-life threatening levels of
toxicity continued on to a third course of vaccination (Table
1). The patients were evaluated at the beginning and end of
each course to study clinical effects and to determine toxicity
levels (Raez, et. al. 2003).
The results of the above study, as shown in Table 2, indicate an
increase in CD8 T cell response in all but one patient. Clinically,
however, the results were less profound. Only 27% of the patients

Table 1

Course 1
Study entry

1

Weeks on
Study
Pre-entryevaluation

2

4

6

1

2

3

Course 2
7

8

10

12

4

5

6

Course 3
13

14

16

18

7

8

9

19

x

Immunization

Table 2, Clinical and Immunological response

Previous

Survival
(months)

Time to
progression
(months)

Preimmune

First
course

Second
course

Third
course

190

C+R

10

-

0

190

ND

ND

NE

NE

C

15

-

0.2

ND

ND

ND

PD

25

C+S

18

-

0

25

ND

ND

1002 A2

PD

1.6

C+S

22

-

41

65

ND

ND

1009 A2

PD

6.5

C

3

-

2

13

ND

ND

1010 A2

PR

41

S

27+

3

3.8

46

88

157

1011 A2

PD

19

C

11

-

3

30

57

ND

1013 A2

PD

34

C+R+S

2

-

5.2

164

178

ND

1014 A2

SD

19

C+S

13+

3

1.6

30

30

25

1015 A2

PD

0

C+R

7

-

0

0

ND

ND

1003 non

SD

134

S

31+

26+

1

134

113

84

1004 non

SD

424

C+R

23

11

0

424

232

>450

1006 non

PD

9.3

C+S

30+

-

16

150

ND

ND

1007 non

SD

14

C+R+S

29+

23+

1.2

2.8

0.8

0/17

1008 non

PD

32

C

6

-

5.6

178

ND

ND

Patient #
HLA

Response

Fold titer
increase

1005 A1

PD

1012 A1
1001 A2

PD=progressive disease; PR=partial response; SD=stable disease; ND=not determined; C=chemotherapy; R=radiation therapy; S=supportive
care; NE=not evaluable
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showed stable disease progression while another 7% showed a
partial response. This total clinical response of 33% suggests that
immunotherapy may be a viable option but requires further study
to assess clinical effectiveness. (Raez, et. al. 2003)
The vaccine used in this study was developed by Dr. N. Savaraj
through modification of a cell line harnessed from a patient in 1994.
The cells were rendered incapable of colonizing ensuring they
would not cause any harm to study participants. However, perhaps
a more effective albeit more expensive method, demonstrated at
the Johns Hopkins School of Medicine (Perica, et.al. 2015), may be
to extract a patient’s own CD8 T cells from the vicinity of the
tumor and subsequently culture them in vitro. This would ensure
that the T cells would be reactive to the patient’s own cancerous
cells. Using pharmaceuticals to regulate the patient’s regulatory T
cells, the CD8 T cells harnessed in vitro can be reinserted with free
rein to target cancerous cells (Perica, et.al. 2015).

Figure 1

Phan, Rosenberg, 2013

44

Adoptive cells transfer is a treatment in which immune cells
harnessed in vitro are transferred to a patient to give him specific immune functions. To treat cancer patients using adoptive
cell transfer, a piece of a tumor is removed from the body, so
that T cells can be removed from the tumor, and stimulated to
grow rapidly in vitro.These T cells are then infused back into the
patient to target and kill cancer cells (Figure 1).
When attempted on patients with metastatic melanoma, adoptive cell transfer showed potential as an effective treatment
although admittedly it had limited clinical results. A trial of 20
metastatic melanoma patients were treated with adoptive cell
transfer and given IL-2 to stimulate the transferred T cells. The
results revealed tumor regression in multiple sites in 11 of the
20 patients studied (Phan, Rosenberg, 2013). However, it should
be noted that although IL-2 promotes the growth and function
of transferred T cells, its addition may also help regulatory T cell
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suppress these transferred T cells thus countering the intended
effect and perhaps limiting the overall effectiveness of the treatment. This indicates that adoptive cell transfer may have a place
in the pursuit of a cure for cancer but it does require some
further fine tuning.
Depletion of immune cells and other immune elements before
adoptive cell transfer of CD 8 T cells in mice has been shown to
increase the effectiveness of transferred T cells (Gattinoni et. al.,
2005). It has been proposed that depleting the immune system
of its natural elements keeps regulatory T cells from turning off
anti-cancer CD 8 T cells transferred during adoptive cell transfer. Additionally, adoptive cell transfer helps lower the immune
system’s tolerance of the cancerous “self-antigens” by selecting
and activating highly specific T cells, mostly CD 8 T cells, and by
changing the body’s internal environment to one that is more
receptive to these cells.

A recent study looked at 13 metastatic melanoma patients who
received immunodepleting chemotherapy specifically targeted
to regulatory T cells. The patients were then injected with in
vitro cultured T cells as well as IL-2. Because the patients first
received immunodepleting chemotherapy, in this study the addition of IL-2 avoided the adverse effect of activating regulatory T
cells.This allowed for highly favorable results (Table 3) that were
significantly more efficient than the results of the study involving
non-small-cell carcinoma patients. Of the 13 patients, 6 showed
positive clinical responses, and 4 showed mixed responses consisting of considerable shrinkage of at least one tumor. Although
the study was relatively small and was limited to melanoma patients, it nevertheless demonstrates the potential of adoptive
cell transfer in treating cancer patients (Dudley et. al., 2002).
In a similar trial, metastatic melanoma patients were treated with
different levels of immunodepletive therapy prior to adoptive cell

Table 3
Patient Demographics, Treatments Received, and Clinical Outcomes.
Treatment

Patient

Age/Sex

Cells
infused
(10^-10)

1

18/M

2.3

11/39

Other

9

Lymph(axillary
nodes mesenteric
pelvic)

PR (24+)

None

2

30/F

3.5

83/15

MART-1
gp100

8

Cutaneous, subcutaneous

PR (8)

Vitiligo

3

43/F

4.0

44/58

gp100

5

Brain, cutaneous,
liver,lung

NR

None

4

57/F

3.4

56/52

gp100

9

Cutaneous, subcutaneous

PR (2)

None

5

53/M

3.0

16/85

Other

7

Brain, lung, lymph
nodes

NR-mixed

None

6

37/F

9.2

65/35

Other

6

Lung, intraperitoneal,
subcutaneous

PR (15+)

None

7

44/M

12.3

61/41

MART-1

7

Lymph nodes, subcutaneous

NR-mixed

Vitiligo

8

48/M

9.5

48/52

gp100

12

Subcutaneous

NR

None

9

57/M

9.6

84/43

MART-1

10

Cutaneous, subcutaneous

PR (10+)

Vitiligo

10

55/M

10.7

96/2

MART-1

12

Lymph nodes, cutaneous, subcutaneous

PR (9+)

Uveitis

11

29/M

13.0

96/3

MART-1

12

Liver, pericardial,
subcutaneous

NR-mixed

Vitiligo

12

37/F

13.7

72/74

MART-1

11

Liver, lung, gallbladder,
lymph nodes

NR-mixed

None

13

41/F

7.7

92/8

MART-1

11

Subcutaneous

NR

None

CD8/CD4
phenotype (%)

Antigen
specificity

IL-2
(doses)

Sites of
evaluable
Metastases

Response
duration
(months)

Autoimmunity

PR = Partial Response, NR = No Response

Dudley et. al., 2002
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transfer in order to establish a level of immunodepletion that would
best enhance this treatment protocol (Rosenberg et. al., 2011). One
group of 43 patients received a nonmyeloablative preparative regimen, a less toxic method of immunodepletion. A second and third
group of 25 patients each, received a more toxic total body irradiation of 2 Gy and 12 Gy (Dept. of Homeland Security 15), respectively, in addition to a non-myeloablative preparative regimen. All
three groups were subsequently treated with adoptive cell transfer
(Rosenberg et. al., 2011).
The results of this study (Table 4) showed that at higher levels of
immunodepletion positive clinical outcomes following adoptive
cell transfer increased. In the group that received only a non-myeloablative preparative regimen, 49% of subjects showed an overall
response while 5% showed complete response. The group that
received 2 Gy of total body irradiation exhibited slightly higher incidence of overall response at 52%, but showed a large increase in
complete response at 20%. The group that received 12 Gy of total
body irradiation showed a marked overall response of 72% with
complete response at 40%, indicating that the greater the immunodepletion the greater the clinical outcome of adoptive cell transfer
(Rosenberg et. al., 2011).

Table 4
Regimen

No. of
Patients

Partial
Response
n (%)

Complete
Response
n (%)

Overall
Response
n (%)

No TBI

43

16 (37)

5 (12)

21 (49)

2 GY TBI

25

8 (32)

5 (20)

13 (52)

12 GY TBI

25

8 (32)

10 (40)

18 (72)

Total

93

32 (34)

20 (22)

52 (56)

TBI=total body irradiation, TIL=tumor-infiltrating lymphocyte

Phan, Rosenberg, 2013
One possible method to increase the overall effectiveness of
adoptive cell transfer and such positive results is to harness
a patient’s own CD 8 T cells to ensure that the T cells are as
specific to the cancer cell antigens as possible to. However, this
is likely a complicated task as it would require development
of a “new drug” for every patient. Another method that may
enhance the results of adoptive cell transfer is to take a sample
of the patients own cancer cells and test CD 8 T cell reactivity
to the cancer antigens thereby ensuring a highly reactive T cell
response. In another experiment, 20 metastatic melanoma patients received a less intense form of immunodepletion called
nonmyeloablative preparative regimen. However, no patient received total body irradiation. In this trial, however, T cells were
taken directly from the actual patients’ tumor and grown quickly in vitro, as opposed to using previously developed anti-tumor
T cells. This may have helped ensure T cells would be highly
specific and highly reactive to the patients’ own cancerous cells.
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Of the 20 patients treated, 10 had an overall response, of
which 2 had a complete remission and 8 had a partial remission. Additionally, 4 patients had stable disease, and 6 had progressive disease for an overall response of 70% (Besser et.
al., 2010). The results show that nonmyeloablative preparative
regimen, coupled with adoptive cell transfer that uses cells
harnessed from patients own tumors can be an effective treatment. Furthermore, analysis of the results may show that the
results are more positive then what is seen on the surface. Of
the 6 patients with progressive disease after treatment, all 6
started with stage M1c melanoma, which represents the stage
in which the tumor has traveled to vital organs (excluding the
lungs) or when the tumor has traveled to other areas and
the patient shows elevated levels of low-density lipoprotein
(“How is Melanoma Staged”). At this stage the cancer cells
may have been too numerous for the transferred T cells.
However, all patients with stages below M1c melanoma and
even some patients with stage M1c melanoma showed at least
some response to adoptive cell transfer, either complete response, partial response, or stable disease. This indicates that
adoptive cell transfer using patient’s own T cells, combined
with nonmyeloablative preparative regimen for immunodepletion is an effective treatment for early stages of metastatic
melanoma patients.
This trial, in which patients received only nonmyeloablative
preparative regimen for immunodepletion prior to adoptive
cell transfer, significantly outperformed the previously mentioned trial in which patients received only nonmyeloablative
preparative regimen for immunodepletion prior to adoptive
cell transfer. One possible explanation may be that this trial
used T cells taken from removed portions of the patients own
tumor, ensuring that the T cells used were highly reactive to
the patients cancerous cells.
As previously stated, immunodepletion prior to adoptive cell
transfer increases the effectiveness of the treatment. However,
immunodepletion effects the entire immune system, which can
have life threatening side effects. Therefore further study to
determine key components that effect the effectiveness of
adoptive cell transfer and how to precisely block them may
be helpful.
The most obvious immune element that would reduce the
effectiveness of adoptive cell transfer is regulatory T cells.
When developing T cells and B cells, the body has mechanisms
through which it ensures than no immune cell is released that
reacts to self-antigens; however, the system is not foolproof.
Regulatory T cells restrain the few immune cells that get
through those mechanisms and suppress them ensuring that
no self-cells are targeted by the immune system.

Active Immunotherapy and Adoptive Cell Transfer

It has been shown that regulatory T cells suppress anti-cancer
CD 8 T cells in vitro (Antony et. al., 2005). It would be logical
to hypothesize that regulatory T cells would also effect the T
cells transferred during adoptive cell transfer. To test for a correlation between regulatory T cells and adoptive cell transfer,
tumor bearing mice were treated with adoptive cell transfer.
Some mice were then injected with anti-Thy-1.2 antibody and
complement to suppress function of regulatory T cells, while
others were given active regulatory T cells. The results showed
that when regulatory T cell function was turned off the transferred T cells destroyed the cancerous cells. However, when
active regulatory T cells were added the size of the tumors
continued growing exponentially (North, 1982). This shows
that regulatory T cells have a large impact on the effectiveness
of adoptive cell transfer.
Although regulatory T cells decrease the effectiveness of adoptive cell transfer, simply turning them off while leaving the rest
of the immune system intact would allow surviving immune
cells that recognize self-antigens to attack patients’ healthy
cells causing autoimmune disease.
One method to reduce the effect of regulatory T cells on adoptive cell transfer without effecting the entire immune system
may be to induce apoptosis only in regulatory T cells in close
proximity to the tumor. This would allow the transferred T
cells to operate in an environment conducive to their function,
while allowing regulatory T cells in other areas of the body to
operate freely avoiding autoimmune disease.
Recently, it was suggested that the protein FasL-Fc can be used
to deplete regulatory T cells located only in tumors (Chen et.
al., 2007). To confine the protein FasL-FC to the tumor, a protein is incorporated into cell membranes and acts as a trap
for the Fc portion of FasL-Fc, not allowing it to escape the
confines of the tumor (Chen, Zheng, Tykocinski, 2000). To test
this suggestion, tumor bearing mice were injected with FasL-Fc
in the tumor region. The results showed a significant increase
in apoptosis of regulatory T cells in the tumors treated with
FasL-Fc, indicating this may be a viable option to decrease the
regulatory T cell effect on adoptive cell transfer without effecting the entire immune system (Chen et. al., 2007).
To test the actual effect of the protein FasL-Fc on adoptive cell
transfer, tumor bearing mice were treated with both FasL-Fc
and adoptive cell transfer. The results were a significant retardation of tumor growth in a large portion of mice. Additionally,
complete tumor regression was seen in 53% of the mice (Chen
et. al., 2007). This indicates that using the protein FasL-Fc may
be a viable option to eliminate the effect of regulatory T cells
on adoptive cell transfer while allowing the immune system to

operate regularly and without the risk of autoimmune effects.
To determine the impact of other immune elements on adoptive cell transfer, tumor bearing mice were tested and the results analyzed. In many studies, after irradiation of cancer bearing mice lacking regulatory T cells, effectiveness of adoptive cell
transfer increased. This indicates that regulatory T cells are not
the only elements responsible for decreased effectiveness of
adoptive cell transfer (Gattinoni et. al., 2005).
One hypothesis is that Natural Killer cells act as sinks for cytokines responsible for survival, proliferation, and function of
transferred CD 8 T cells (Gattinoni et. al., 2005). Host Natural
Killer cells, also in need of cytokines, compete for the same
cytokines necessary to support the transferred T cells leading to a limited amount of cytokines available to support the
transferred T cells. To test this hypothesis, tumor bearing mice
lacking endogenous B cells and T cells, including regulatory T
cells, were treated with anti-NK1.1 antibody to decrease the
number of Natural Killer cells to the number found after irradiation of the entire immune system. They were then treated
with adoptive cell transfer and compared to mice not given
the anti-NK1.1 antibody and treated with adoptive cell transfer. The results showed that removal of Natural Killer cells
increased the effectiveness of adoptive cell transfer, indicating
that Natural Killer cells play an important role in the function
of transferred CD 8 T cells (Gattinoni et. al., 2005).
One way to avoid the effects of cytokine sinks may be to precisely determine which cytokines the Natural Killer cells sink,
and stimulate an increase of their production giving the transferred T cells access to those cytokines.
To determine the effects of cytokines on adoptive cell transfer,
different cytokines were removed and added to tumor bearing
mice treated with adoptive cell transfer. Results indicated that
the cytokline IL-7 was needed to maintain survival and continued growth of transferred T cells, but was not necessary to
maintain function of the T cells. Conversely, IL-15 was necessary to maintain function, but did not play a part in survival and
proliferation of transferred T cells. This shows that increasing
both IL-7 and IL-15 at the same time increases the transferred
T cells effectiveness against tumors, while decreasing both IL-7
and IL-15 at the same time would decreases the transferred T
cells effectiveness against tumors (Gattinoni et. al., 2005).
These findings indicate that there may be a path by which regulatory T cells can be eliminated from the area of the tumor
(Chen et. al., 2007), and transferred CD 8 T cells can be stimulated to proliferate and enhance their effector functions without effecting the entire immune system (Gattinoni et. al., 2005).

47

Philip Jay Cynamon

Conclusion
In conclusion, increasing CD 8 T cell count alone is not the most
effective way to use T cells to fight cancer. Instead immunodepletion together with an increase in anti-cancer T cells delivered
through adoptive cell transfer is an effective approach that has
been shown to be effective in humans with metastatic melanoma. Other factors besides immunodepletion also effect the
results of adoptive cell transfer such as cytokines, and the origin
of the T cells injected. The key to adoptive cell transfer success
with limited side effects, is the balance of all elements involved
which is a large task and requires further study but does seem
possible in the future.
However, for now, adoptive cell transfer is still a relatively new
method of treatment and still requires immunodepletion for
its effectiveness. This can bring with it its own problems, such
as an increased risk of infection and a limited ability to fight
infection. Additionally, most trials of adoptive cell transfer on
humans have been limited to melanoma patients, making further
research necessary for it to be used to fight other cancers. To
that effect, further studies are currently underway to broaden
this treatment to fight other cancers including, lymphoma, leukemia, and neuroblastoma (Deng et. al., 2014) giving hope to
cancer patients all over the world.
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